Q BioMed Inc. (OTCMKTS:QBIO – Get Rating) saw a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 45,900 shares, an increase of 50.0% from the August 15th total of 30,600 shares. Based on an average daily trading volume, of 1,913,000 shares, the days-to-cover ratio is currently 0.0 days.

Q BioMed Stock Performance

QBIO remained flat at $0.02 during trading on Friday. 69,167 shares of the company's stock traded hands, compared to its average volume of 396,902. Q BioMed has a 12 month low of $0.02 and a 12 month high of $0.76. The stock's 50-day moving average is $0.05 and its 200 day moving average is $0.13. The stock has a market capitalization of $1.41 million, a price-to-earnings ratio of -0.08 and a beta of 2.39.

Q BioMed (OTCMKTS:QBIO – Get Rating) last announced its earnings results on Thursday, July 28th. The company reported ($0.06) earnings per share for the quarter. The firm had revenue of $0.17 million for the quarter.

Q BioMed Company Profile

Q BioMed Inc, a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain.

See Also

• Get a free copy of the StockNews.com research report on Q BioMed (QBIO)
• Stock Market: 3 Islands Of Strength In A Sea Of Red
• 3 Banks Worth Considering For Q4
• Is There a Cure for What is Ailing Teladoc Stock?
• MarketBeat: Week in Review 9/12 – 9/16
• No One Told These 3 Stocks It's a Down Week

Receive News & Ratings for Q BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q BioMed and related companies with MarketBeat.com's FREE daily email newsletter.